Intra-articular injection of indomethacin–methotrexate in situ hydrogel for the synergistic treatment of rheumatoid arthritis

2020 ◽  
Vol 8 (5) ◽  
pp. 993-1007 ◽  
Author(s):  
Na Yin ◽  
Xueting Guo ◽  
Rong Sun ◽  
Hongbing Liu ◽  
Lihua Tang ◽  
...  

Intra-articular injection of a temperature-sensitive hydrogel containing D-NPs formed by PEI-SS and IND and MTX.

2021 ◽  
Vol 9 (1) ◽  
pp. 221-237
Author(s):  
Zhiqiang Zhang ◽  
Anning Li ◽  
Xingqi Min ◽  
Qunqun Zhang ◽  
Jun Yang ◽  
...  

A temperature-sensitive hydrogel encapsulating tegafur and protoporphyrin IX dimers could be delivered intratumorally for synergetic chemotherapy and photodynamic therapy.


Nanoscale ◽  
2020 ◽  
Vol 12 (15) ◽  
pp. 8546-8562 ◽  
Author(s):  
Na Yin ◽  
Xinyi Tan ◽  
Hongbing Liu ◽  
Fengming He ◽  
Ning Ding ◽  
...  

The D/siRNA-NGel was constructed to alleviate pain and swelling, delay the progression of RA, and reverse cartilage and bone disruption.


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Thomas B. G. Poulsen ◽  
Dres Damgaard ◽  
Malene M. Jørgensen ◽  
Ladislav Senolt ◽  
Jonathan M. Blackburn ◽  
...  

AbstractThe presence or absence of autoantibodies against citrullinated proteins (ACPAs) distinguishes two main groups of rheumatoid arthritis (RA) patients with different etiologies, prognoses, disease severities, and, presumably, disease pathogenesis. The heterogeneous responses of RA patients to various biologics, even among ACPA-positive patients, emphasize the need for further stratification of the patients. We used high-density protein array technology for fingerprinting of ACPA reactivity. Identification of the proteome recognized by ACPAs may be a step to stratify RA patients according to immune reactivity. Pooled plasma samples from 10 anti-CCP-negative and 15 anti-CCP-positive RA patients were assessed for ACPA content using a modified protein microarray containing 1631 different natively folded proteins citrullinated in situ by protein arginine deiminases (PADs) 2 and PAD4. IgG antibodies from anti-CCP-positive RA plasma showed high-intensity binding to 87 proteins citrullinated by PAD2 and 99 proteins citrullinated by PAD4 without binding significantly to the corresponding native proteins. Curiously, the binding of IgG antibodies in anti-CCP-negative plasma was also enhanced by PAD2- and PAD4-mediated citrullination of 29 and 26 proteins, respectively. For only four proteins, significantly more ACPA binding occurred after citrullination with PAD2 compared to citrullination with PAD4, while the opposite was true for one protein. We demonstrate that PAD2 and PAD4 are equally efficient in generating citrullinated autoantigens recognized by ACPAs. Patterns of proteins recognized by ACPAs may serve as a future diagnostic tool for further subtyping of RA patients.


Pharmaceutics ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 567
Author(s):  
Ivona Tomić ◽  
Sandra Miočić ◽  
Ivan Pepić ◽  
Dubravka Šimić ◽  
Jelena Filipović-Grčić

Acne vulgaris is a common, multifactorial, inflammatory skin disease affecting the pilosebaceous unit. Topical therapy is the first choice in the treatment of mild to moderate acne, and azelaic acid (AZA) is one of the most commonly used drugs. The aim of this study was to evaluate the safety and efficacy of a low-dose azelaic acid nanocrystal (AZA-NC) hydrogel in the treatment of mild to moderate facial acne. The study was designed as a double-blind, randomized controlled trial. Patients were randomized to treatment with AZA-NC hydrogel, 10%, or AZA cream, 20%, administered in quantities of approximately 1 g twice daily for 8 weeks. Efficacy of therapy was measured by the number of lesions and safety by the frequency and severity of adverse events. At week 8, the success rate of treatment with AZA-NC hydrogel, 10%, was 36.51% (p < 0.001) versus 30.37% (p < 0.001) with AZA cream. At week 8, treatment with AZA-NC hydrogel, 10%, resulted in a significant reduction in total inflammatory lesions from baseline of 39.15% (p < 0.001) versus 33.76% (p < 0.001) with AZA cream, and a reduction in non-inflammatory lesions from baseline of 34.58% (p < 0.001) versus 27.96% (p < 0.001) with AZA cream, respectively. The adverse event rate was low and mostly mild.


2005 ◽  
Vol 52 (10) ◽  
pp. 3269-3278 ◽  
Author(s):  
István Gál ◽  
Éva Bajnok ◽  
Sándor Szántó ◽  
Bara Sarraj ◽  
Tibor T. Glant ◽  
...  

1995 ◽  
Vol 6 (7) ◽  
pp. 534-540 ◽  
Author(s):  
Koji Achiha ◽  
Rika Ojima ◽  
Yuji Kasuya ◽  
Keiji Fujimoto ◽  
Haruma Kawaguchi

2014 ◽  
Vol 108 ◽  
pp. 26-33 ◽  
Author(s):  
Zesheng Lv ◽  
Longlong Chang ◽  
Xingwen Long ◽  
Jianping Liu ◽  
Yuzhang Xiang ◽  
...  

2010 ◽  
Vol 148-149 ◽  
pp. 1427-1430 ◽  
Author(s):  
Kui Lin Deng ◽  
Li Rong Dong ◽  
Yu E Shi ◽  
Yu Bo Gou ◽  
Qian Li ◽  
...  

As a drug delivery carrier, a novel pH/temperature sensitive bead (pTSB) with core-shelled structure from poly(N-acryloylglycine) (PAG), copoly(N-acryloylglycine methyl este and N-acryloylglycine ethyl ester) was prepared by two steps. In pH=7.4 phosphate buffer solution (PBS), the cumulative release amount of indomethacin loaded in the pTSB was about 60.1 % within 500 mins, but this value only reached to 22.3 % in pH=2.1 PBS. The release behaviors of indomethacin from pTSB also exhibited a remarkable dependence on PAG content in the core. Additionally, the release rate of indomethacin was much faster at 18 oC than that at 37 oC due to the temperature sensitivity of poly(N-acryloylglycinates). The experimental results indicate that pTSB seems to have a potential application in the drug release system controlled via pH or temperature in the biomedical fields.


Sign in / Sign up

Export Citation Format

Share Document